

S2 Table. Individual patient dosimetry data

	Participant		
	1	2	3
Injected activity (GBq)	5.70	5.85	5.64
Absorbed doses per injected activity (mGy/MBq)			
Adrenals	0.033	0.054	0.019
Brain	0.041	0.043	0.002
Breasts	0.042	0.043	0.005
Gallbladder wall	0.066	0.061	0.033
Lower large intestine wall	0.043	0.045	0.003
Small intestine	0.046	0.047	0.007
Stomach wall	0.046	0.048	0.008
Upper large intestine wall	0.048	0.048	0.009
Heart wall	0.049	0.049	0.011
Kidneys	0.367	0.570	0.563
Liver	n/a ^{a)}	n/a ^{a)}	n/a ^{a)}
Lungs	0.047	0.047	0.009
Muscle	0.043	0.045	0.005
Pancreas	0.054	0.053	0.083
Red marrow	0.043	0.044	0.073
Osteogenic cells	n/a ^{a)}	n/a ^{a)}	n/a ^{a)}
Skin	0.041	0.043	0.066
Spleen	0.060	0.280	0.190
Testes	0.041	0.043	0.067
Thymus	0.043	0.045	0.070
Thyroid	0.042	0.044	0.068
Urinary bladder wall	0.043	0.045	0.069
Total body effective dose (mSv/MBq)	0.11	0.09	0.15

^{a)}Liver and osteogenic cell dosimetry was hampered by the presence of extensive metastases, which are inherent to the clinical status of the enrolled patients.